Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.
A large proportion of mobile apps for self-management of blood glucose do not provide real-time decision support for users with type 2 diabetes, researchers report.
The endothelin receptor antagonist atrasentan may reduce the risk for kidney disease progression among certain high-risk patients with type 2 diabetes and kidney disease, indicate findings from the SONAR trial.
Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show.
Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.
Adding the SGLT1/2 inhibitor sotagliflozin to insulin treatment improves glycemic and non-glycemic outcomes among people with type 1 diabetes, but at the cost of an increased risk for diabetic ketoacidosis, researchers report in The BMJ.
The potent lipid-lowering effects of the PCSK9 inhibitor evolocumab have been demonstrated in a randomized trial conducted specifically in people with type 2 diabetes.
An interim analysis of EMPRISE shows reductions in heart failure risk with empagliflozin in real-world users that match those reported in the EMPA-REG OUTCOME trial.
People with type 2 diabetes are more likely to experience cardiovascular events, particularly myocardial infarction, within 3 years of starting glucose-lowering therapy if they have pre-existing ischemic heart disease, research shows.
Research using the Swedish National Diabetes Registry shows that diabetes confers a particularly high relative risk for mortality and multiple cardiovascular disease outcomes in people who are young when diagnosed.
Flash glucose monitoring significantly reduces time in hyperglycemia or hypoglycemia in people with diabetes at high risk for either outcome, with the benefit sustained for at least 6 months, real-world study data show.
People with type 2 diabetes experience an overall decline in renal function over time, but there is substantial variation among individuals, with some seeing an improvement in estimated glomerular filtration rate, researchers report.
Insulin pumps and multiple daily injections deliver similar glycemic control and safety profiles when allocated alongside education and support at the point of type 1 diabetes diagnosis, say researchers.
Objective analysis of urine samples shows that some patients with type 2 diabetes do not take their antihypertensive, antihyperlipidemic, and oral hypoglycemic medications as prescribed.
The frequency at which people with type 1 diabetes experience hypoglycemia decreases during the first 30 days after they switch to a continuous glucose monitor that incorporates a predictive low-glucose alert, research shows.
Researchers show that closed-loop insulin delivery achieves markedly better glucose control than standard insulin management in hospitalized patients with hyperglycemia receiving enteral or parenteral nutrition.
Relying solely on glycated hemoglobin to diagnose type 2 diabetes will miss a substantial proportion of cases and thus the opportunity for early intervention, say researchers.
The association between poor glycemic control during pregnancy and subsequent risk for cardiovascular disease extends to women without gestational diabetes, study findings suggest.
Cardiovascular autonomic neuropathy is reversible in people with type 2 diabetes, report Korean researchers who found that age was the most important predictor of recovery.
Oral semaglutide offers greater efficacy for glucose control and weight loss when compared with sitagliptin for people with type 2 diabetes, although with more adverse events at the highest dose, show the PIONEER 3 findings.